Structure-based Antiviral Design against HTLV-1 Protease

基于结构的 HTLV-1 蛋白酶抗病毒设计

基本信息

项目摘要

Project Summary Human T-cell leukemia virus type-1 (HTLV-1) is an oncogenic human retrovirus affecting over 20 million people worldwide. HTLV-1 infection can cause adult T-cell lymphoma (ATL) and other serious inflammatory diseases. Estimates report that 5-10% of HTLV-1 infected patients will develop a serious condition such as ATL, which has poor 4-year survival and high relapse rates. HTLV-1 has persistent infection rates across the globe and reaches up to 45% prevalence in certain communities. Despite this impact on human health, there are no direct-acting antivirals (DAAs) or vaccines against HTLV-1. HIV-1 and HTLV-1 are from the same viral family and encode for a homodimeric aspartyl protease crucial for cleavage of functional proteins from viral polyproteins. The activity of HIV-1 and HTLV-1 protease is essential to their viral life cycles. The Schiffer laboratory has extensive experience with viral protease crystallography and inhibition, especially with viral proteases for HIV-1, HCV NS3/4A, and SARS-CoV-2 main protease. This expertise uniquely positions me to design, synthesize, and characterize potent, resistance-thwarting protease inhibitors against HTLV-1 protease. Resistance-preventing DAA design is essential because of the selective pressure applied during DAA treatment. An ideal and proven strategy for developing a highly potent and resistance-preventing viral protease inhibitor is to target the active site through rational design using the substrate envelope. The substrate envelope for HTLV-1 protease has not been characterized and we lack a detailed understanding of the protease substrate specificity. I hypothesize that by translating strategies from our design of HIV-1 protease inhibitors, namely characterizing HTLV-1 protease’s substrate specificity, I can design potent and resistance-preventing DAAs for HTLV-1 protease. Aim 1: Characterize the structural basis for HTLV-1 protease substrate specificity. HTLV-1 protease cleaves six substrates by recognizing cleavage sites between individual proteins of the viral polyprotein. I will investigate the molecular basis of this recognition underlying protease specificity by determining cocrystal structures of the protease with bound substrates. The conserved volume inhabited by the substrates will define the substrate envelope and inform inhibitor design for HTLV-1 protease. Aim 2: Rationally design, synthesize, and characterize inhibitors of HTLV-1 protease to optimize potency. HIV-1 and HTLV-1 proteases share an active site amino acid sequence identity of 45% and high structural similarity. Therefore, I will begin inhibitor design by testing a selection of our in-house HIV-1 protease inhibitors, which have already shown low (1 µM) to moderate (30 nM) potency against HTLV-1 protease. I will combine experimental inhibition assays with cocrystal structure analysis to identify lead compounds for inhibitor design. I will leverage substrate specificity of the protease by moving inhibitor design towards compounds that mimic the shape of substrates, leveraging the substrate envelope (Aim 1), and the interactions between protease and substrate. I aim to produce novel, highly potent (sub-nM) inhibitors that will be promising DAAs for further investigation against HTLV-1.
项目摘要 人类T细胞白血病病毒1型(HTLV-1)是一种致癌的人类逆转录病毒,影响超过2000万人 国际吧HTLV-1感染可引起成人T细胞淋巴瘤(ATL)等严重炎症性疾病。 据估计,5-10%的HTLV-1感染患者将发展成严重的病症,如ATL,其具有 4年生存率低,复发率高。HTLV-1在地球仪上具有持续的感染率, 在某些社区的患病率高达45%。尽管对人类健康有这种影响, 抗病毒药物(DAA)或针对HTLV-1的疫苗。HIV-1和HTLV-1来自相同的病毒家族, 一种对从病毒多聚蛋白中切割功能蛋白至关重要的同型二聚体乙酰基蛋白酶。活动 HIV-1和HTLV-1蛋白酶的活性对它们的病毒生命周期至关重要。希弗实验室拥有广泛的 具有病毒蛋白酶晶体学和抑制的经验,尤其是HIV-1、HCV病毒蛋白酶 NS 3/4A和SARS-CoV-2主要蛋白酶。这种专业知识使我能够设计,合成, 表征针对HTLV-1蛋白酶的有效的抵抗性阻碍蛋白酶抑制剂。防阻 DAA设计是必不可少的,因为在DAA治疗过程中施加的选择性压力。一个理想的和证明 开发高效且可预防耐药性的病毒蛋白酶抑制剂的策略是针对活性物质 网站通过合理的设计使用基板信封。HTLV-1蛋白酶的底物包膜没有 已经被表征,我们缺乏对蛋白酶底物特异性的详细了解。我假设 通过翻译我们设计的HIV-1蛋白酶抑制剂的策略,即表征HTLV-1蛋白酶的 底物特异性,我可以设计有效的和耐药性预防的DAA的HTLV-1蛋白酶。 目的1:研究HTLV-1蛋白酶底物特异性的结构基础。HTLV-1蛋白酶 通过识别病毒多蛋白的单个蛋白质之间的切割位点来切割六种底物。我会 通过测定共晶体来研究这种识别的分子基础, 蛋白酶与结合底物的结构。基质占据的守恒体积将定义 该底物包被并通知针对HTLV-1蛋白酶的抑制剂设计。目标二:合理设计、合成, 并表征HTLV-1蛋白酶的抑制剂以优化效力。HIV-1和HTLV-1蛋白酶共享一个 活性位点氨基酸序列同源性为45%,结构相似性高。因此,我将开始抑制剂 通过测试我们的内部HIV-1蛋白酶抑制剂的选择来设计,这些抑制剂已经显示出低(1 µM)至 对HTLV-1蛋白酶的中等(30 nM)效力。我将联合收割机实验性抑制试验与共晶 结构分析以鉴定用于抑制剂设计的先导化合物。我将利用底物的特异性 通过将抑制剂设计转向模拟底物形状的化合物,利用底物的性质, 底物包被(Aim 1),以及蛋白酶与底物之间的相互作用。我的目标是创作小说, 有效的(亚nM)抑制剂,将是有前途的DAA进一步研究对HTLV-1。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah N Zvornicanin其他文献

Sarah N Zvornicanin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334970
  • 财政年份:
    2024
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
  • 批准号:
    2400195
  • 财政年份:
    2024
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334969
  • 财政年份:
    2024
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
  • 批准号:
    23K04919
  • 财政年份:
    2023
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
  • 批准号:
    22KJ2957
  • 财政年份:
    2023
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
  • 批准号:
    23K04494
  • 财政年份:
    2023
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
  • 批准号:
    23K13831
  • 财政年份:
    2023
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
  • 批准号:
    2238379
  • 财政年份:
    2023
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
  • 批准号:
    2154399
  • 财政年份:
    2022
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
  • 批准号:
    RGPIN-2019-06633
  • 财政年份:
    2022
  • 资助金额:
    $ 3.5万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了